Childhood immunization schedule of the Spanish Association of Pediatrics 2003;Calendario vacunal de la Asociación Española de Pediatría 2003

Anales de Pediatria

Volumn 58, Issue 3, 2003, Pages 257-262

  Blanco Quiros A ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Combined vaccines; Immunization schedule; Immunizations; Vaccination strategies; Vaccine preventable diseases; Vaccines

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; JERYL LYNN; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RIT 4385; TETANUS TOXOID; VACCINE;

ADOLESCENT; CHILD; CHILD CARE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MEDICAL SOCIETY; PEDIATRICS; REVIEW; TETANUS PROPHYLAXIS;

EID: 0037832507     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043563     Document Type: Review

References (68)

1. Comité Asesor de Vacunas de la AEP. Calendario vacunal de la AEP 1999. An Esp Pediatr 1999;51:120-6.
2. Comité Asesor de Vacunas de la AEP. Calendario vacunal de la Asociación Española de Pediatría 2001-2002. An Esp Pediatr 2001;55:30-8.
3. Helwig H, Mertsola J, Harvey D, Nicolopoulos D, Schaack JC, Sedlak W, on behalf of the Confederation of European Specialists in Pediatrics (CESP). J Pediatr 1998;157:676-80.
4. Dal-Ré R, Arístegui J, González A. Inmunidad frente a la difteria en adultos jóvenes en España. Med Clin (Barc) 1995;17:676.
5. Garcia-Corbeira P, Dal-Ré R, García de Lomas J, Aguilar L. Low prevalence of diphtheria immunity in the Spanish population: results of a cross-sectional study. Vaccine 1999;17:1978-82.
6. Español M, Muñoz C, Prats G. Inmunidad frente a la difteria de una muestra representativa de la población de Barcelona determinada mediante una técnica inmunoenzimática. Vacunas Investigación y Práctica 2000;1:59-64.
7. Jacobs RL, Lowe RS, Lanier BQ. Adverse reactions to tetanus toxoid. JAMA 1982;247:40.
8. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984;73:31-6.
9. Jones AE, Melville-Smith M, Watkins J, Seagroatt V, Rice L, Sheffield F. Adverse reactions in adolescents to reinforcing doses of plain and adsorbed tetanus vaccines. Community Med 1985;7:99-106.
10. CDC. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40 (N° RR-10):1-28.
11. Servicio de vigilancia epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2000. Bol Epidemiol Semanal 2001;9:101-12.
12. Servicio de vigilancia epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2001. Bol Epidemiol Semanal 2002;10:49-60.
13. Gil A, Oyagüez I, Carrasco P, Gonzalez A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine 2001;19:4791-4.
14. Eiros Bouza JM, Ortiz de Lejarazu R, Orduña Domingo A, Bachiller Luque MR. Estudio seroepidemiológico en niños vacunados frente a tos ferina. An Esp Pediatr 1994;41:285-6.
15. García Corbeira P, Dal-Ré R, Aguilar L, García de Lomas J. Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine 2000;18:2173-6.
16. Nennig ME, Shinefield HR, Edwards KM, Black SB, Fireman BH. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996;275:1672-4.
17. Wright SW. Pertussis infection in adults. South Med J 1998;91:702-8.
18. CDC Pertussis outbreak-Vermont, 1996. MMWR 1997;46:822-6.
19. Campins-Martí M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang L-M, et al. Recommendations are needed for adolescents and adult pertussis immunisation: rationale ans strategies for consideration. Vaccine 2002;20:641-6.
20. Giemprel E, Baron S, Lévy-Bruhl D, Garmier JM, N'jamkepo E, Guiso N. Influence of vaccination coverage on pertussis transmisión in France. Lancet 1999;354:1699-700
21. Moraga FA, Campins Martí M. La tos ferina en el lactante y el adolescente. An Esp Pediatr 2002;56:417-21.
22. World Health Organization. Certification of poliomyelitis eradicaction. European Region, June 2001. Weekly Epidemiological Record 2002;27:221-3.
23. American Academy of Pediatrics. Committee of Infectious Diseases: Prevention of poliomyelitis: recommendations for the use of only inactivated poliovirus vaccine for routine immunization. Pediatrics 1999;104:1404-6.
24. Salleras L, Domínguez A. Prospects for global poliomyelitis eradication. Vacunas, Investigación y Práctica 2000;1:178-87.
25. Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, et al. Economic Evaluation of vaccination programmes. A consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002;20:1-7.
26. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001;10:751-74.
27. Kane M, Banatvala J, Da Villa G. Are booster immunizations hended for lifelong hepatitis B immunity? Consensus statement. Lancet 2000;355:561-5.
28. Lopalco PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M, et al. Hepatitis A and B in children and adolescents-what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2000;19:470-4.
29. Dirección General de Salud Pública. Ministerio de Sanidad y Consumo. Programas de vacunación frente a la hepatitis B en adolescentes. Periodo 1996-1997. Bol Epidemiol Semanal 1998;6:209-10.
30. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
31. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002;67:433-9.
32. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Haemophilus influenzae tipo b (Hib) conjugate vaccines administered in combination with DTP containing acellular pertussis and protection against invasive Hib disease. Lancet 1999;354:2036-68.
33. Schmitt HJ, Zepp F, Muschenbord S, Sumenicht G, Schuind A, Beutel K, et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphteriatetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998;157:208-14.
34. Zepp F, Schuind A, Meyer C, Sanger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 2002;109:e58.
35. Cody Meissner H, Pickering LK. Control of disease attributable to Haemophilus influenzae type b and the national immunization program. Pediatrics 2002;110:820-2.
36. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002;110:653-61.
37. American Academy of Pediatrics. Committee on Infectious Diseases. Age for Routine Administration of the second dose of measles-mumps-rubella vaccine. Pediatrics 1998;101:129-33.
38. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles erradication: Is it in out future? Am J Public Health 2000;90:1521-5.
39. Mateo S, Cano R, García C. Changing epidemiology of meningococcal disease in Spain, 1989-1997. Eurosurveillance 1997;2: 71-4.
40. MacLennan JM, Shackley F, Health PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity and induction of immunologic memory by a serogroup C conjugate vaccine in infants. JAMA 2000;283:2795-801.
41. Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Blatter MM, Sally A, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J 2001;20:153-9.
42. Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999;179:1569-72.
43. Arberter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North Am 1996;10:609-15.
44. Gómez Campderá JA. Vacuna antivaricela. Acta Pediatr Esp 2001;59:345-55.
45. Srabstein JC, Morris N, Larke B, deSa D, Oxon DP, Castelino BB, et al. Is there a congenital varicella syndrome? J Pediatr 1974;84:239-43.
46. Gershon AA, LaRusa P, Steinberg S. Clinical trials in immuno-compromised individuals. Infect Dis Clib North Am 1-996;10:583-94.
47. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccina. JAMA 2000;284:1271-9.
48. Moraga LLop F, García de Miguel MJ, Giangaspro E, Roca J, Baquero F, Gómez Campderá JA, et al. Coste de la hospitalización por varicela en niños inmunocompetentes. Vacunas 2001;2(Supp 1):20-4.
49. Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999;17:1306-11.
50. De Lucas C, Gómez Campderá JA, Navarro Gómez ML, Rodríguez Fernández R. Complicaciones de la varicela en niños previamente sanos. Rev Esp Pediatr 1997;53:320-4.
51. a T, Palomeque Ricao A. Purpura fulminans posvaricela con déficit transitorio de proteína C y proteína S. An Esp Pediatr 1998;49:412-4.
52. Riaza Gómez M, De la Torre Espi M, Mencia Bartolomé S, Molina Cabalero JC, Tamariz-Martel Moreno A. Complicaciones de la varicela en niños. An Esp Pediatr 1999;50:259-2.
53. Casado A, García Calvo M, Pérez A, Rodríguez Créixems M. Incidencia de las infecciones neumocócicas pediátricas en España. Revisión bibliográfica. An Esp Pediatr 2002;57 (Supl 1):7-13.
54. Bernaola E, de Aristegui J, Herranz M, García-Calvo C, Fernández C. Estudio de la incidencia de enfermedad neumocócica invasora entre 0-5 años en el País-Vasco y Navarra. An Esp Pediatr 2002;57:301-9.
55. Pérez C, Solis G, Miguel D, De la Iglesia P, Viejo G, Martín M. Factores predictivos de enfermedad neumocócica invasora: estudio de casos controles. An Esp Pediatr 2002;57:310-6.
56. Pineda Solas V, Pérez Benito A, Domingo Puiggros M, Larramona Carrera H, Segura Prota F, Fontanals Aymerich D. Neumonía neumocócica bacteriémica. An Esp Pediatr 2002;57:408-13.
57. Casado Flores J, Fenol A, Aristegui J, Rodrigo de Liria C, Martinón JM, Fernández C y Grupo para el Estudio de la Meningitis Neumocócica. Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico. An Esp Pediatr 2002;57:287-9.
58. Picazo JJ, Betriu C, Rodríguez-Aviar I, Azahares E, Alí Sánchez B y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA. Enferm Infecc Microbiol Clin 2002;20:503-10.
59. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. The Northern California Kaiser Permanent Vaccine Study Center Group. Efficacy, safety and inmunogenicity of a heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
60. Black S, Shinefield H, Ling S, Hansen J, Fireman B, Spring D, et al. The Northern California Kaiser Permanent Vaccine Study Center Group. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5.
61. Fenoll A, Jado Y, Vicioso D, Berron S, Yuste JE, Casal J. Streptococcus pneumoniae in children in Spain: 1990-1999. Acta Pediatr 2000;435 (Suppl):44-50.
62. Pineda V, Fontanals D, Larramona H, Domingo M, Anton J, Segura F. Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona, Spain. Acta Paediatr 2002;91:1251-6.
63. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Incidencia de la infección neumocócica invasora en niños menores de dos años. Vacuna neumocócica conjugada heptavalente. Situación en España. An Esp Pediatr 2002;57:287-9.
64. Comité Asesor de Vacunas de la Asociación Española de Pediatría. La enfermedad neumocócica y su prevención. Vacuna neumocócica conjugada heptavalente. An Esp Pediatr 2002;56:79-90.
65. Liese JG, Stojanov S, Berut F, Minini P, Harzer E, Jow S, et al, and Munich Vaccine Study Group. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP-T-HBs) administered at 2, 4, 6 and 12-14 months of age. Vaccine 2001;20:448-54.
66. Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schodel F, et al, and Hexavalent Vaccine Trial Study Group. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccine in infants. Pediatr Infect Dis J 2000;19:1119-27.
67. Schmitt HJ, von Kries R, Hassenpflug B, Hermann M, Siedler A, Niessing W, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001;20:767-74.
68. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20 (11 Suppl):S10-8.